Novo Nordisk Partners With Anthropic to Accelerate Drug Discovery Using Claude
· Technology · Wall Street Journal, Economic Times
Novo Nordisk has partnered with artificial intelligence firm Anthropic to use the Claude AI model for accelerating drug discovery processes. The collaboration integrates advanced language models into pharmaceutical research workflows to analyze complex biological data. Drug discovery pipelines often face lengthy timelines and high operational costs before clinical trials begin. The partnership aims to streamline target identification and chemical synthesis using machine learning capabilities.
Why it matters
Pharmaceutical companies are increasingly adopting generative AI to shorten the timeline of drug development and reduce research costs.
Read the original report — Wall Street Journal
Join us on Telegram
Breaking news the moment it lands. At 10,000 members we ship the Android app.